4th Annual G-FINDER Survey Released

Click here for full report.

Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been particularly hard hit, as eight of the top twelve public donors cut their funding in 2010.

While the report shows that funding for TB R&D increased by $30M from 2009 – 2010, annual funding is still barely 25% of the figure suggested by the Stop TB Partnership as adequate to sustain the pace of R&D to bring critically-needed new TB products to the field without delay. Investments by public and philanthropic donors over the past 10 years have built a pipeline of products that will transform TB control. Turning away from these projects means that we will continue to wage the fight against TB with inadequate tools. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients–donors must commit to taking them across the finish line.

Read full report.

Read report highlights.

For those who use Twitter, here are some prepared tweets to highlight the urgent need to maintain funding for TB R&D. To use them:

  1. Sign into twitter
  2. Click any of the links below, which will automatically load
  3. Press “tweet”

Tweet #1

#PDP funding decreased for a 2nd straight year, putting 100+ global health projects in jeopardy. #RnD4NTDs #GFINDER

Click here to automatically load.

Tweet #2

A decade of work built a robust pipeline of new TB drugs. We must see them across the finish line. #RnD4NTDs #GFINDER

Click here to automatically load.

Tweet #3

#TB doesn’t heed a global financial crisis. Global health funding cuts only embolden pandemics. #RnD4NTDs #GFINDER

Click here to automatically load.

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...